0.0000 (0.0000%)
  • Bid / Lots
    5.8900/ 1
  • Ask / Lots
    6.5500/ 1
  • Open / Previous Close
    0.0000 / 6.2400
  • Day Range
  • 52 Week Range
    Low 5.7000
    High 14.6400
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 6.4
09:32 ET3566.4
09:39 ET3006.49
09:44 ET2506.535
09:53 ET2006.6152
09:55 ET2506.42
10:00 ET1376.58
10:04 ET1006.4
10:06 ET2006.4
10:08 ET1666.4
10:11 ET1006.395
10:20 ET1006.3975
10:24 ET6006.49
10:26 ET20006.34
10:27 ET2006.34
10:31 ET2006.3
10:40 ET100346.3
10:45 ET1006.3
10:54 ET1006.33
11:02 ET1006.35
11:07 ET2006.36
11:20 ET10006.5154
11:36 ET4006.33
11:52 ET1006.36
11:54 ET24006.43
11:56 ET22006.405
11:59 ET37006.33
12:10 ET1006.3
12:12 ET4006.465
12:30 ET3006.35
12:37 ET2006.3
01:02 ET1196.44
01:15 ET18406.435
01:18 ET2006.32
01:20 ET3146.32
01:22 ET16756.47
01:24 ET4006.3
01:36 ET8076.3
01:38 ET10006.29
01:40 ET15626.28
01:42 ET24296.25
01:44 ET4006.255
01:45 ET1006.31
01:47 ET27116.23
01:49 ET12006.29
01:51 ET1006.18
01:58 ET2266.29
02:00 ET13676.25
02:02 ET12626.25
02:03 ET3006.25
02:14 ET12006.25
02:16 ET1006.29
02:18 ET12756.2
02:25 ET1006.21
02:36 ET3006.29
02:50 ET1006.3
03:15 ET1006.29
03:37 ET3006.255
03:42 ET1006.28
03:51 ET2006.3
03:55 ET1006.29
03:57 ET3006.3
04:00 ET11696.24
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesGHRS
GH Research PLC
United StatesIMNM
Immunome Inc
United StatesKALV
Kalvista Pharmaceuticals Inc
United StatesIGMS
IGM Biosciences Inc
United StatesACIU
AC Immune SA
United StatesTSHA
Taysha Gene Therapies Inc
As of 2023-12-05

Company Information

GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, it has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). GH002 is its 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. GH003 is its 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.

Contact Information

Joshua Dawson House, Dawson StreetDublin, Ireland D02 RY95


Non-Executive Chairman of the Board
Florian Schonharting
Chief Executive Officer
Theis Terwey
Non-Executive Independent Vice Chairman of the Board
Michael Forer
Vice President - Finance
Julie Ryan
Managing Director, Ireland
Magnus Halle

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.